June 27-29 2017

Boston, MA

Speakers

Expand/Collapse

Larry Weiss
Chief Medical Officer
AOBiome

Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and product commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a multiple patents and is published in the areas of chemistry, electrophysiology, pharmacology, and microbiology. Dr. Weiss is the founder of CleanWell Company.

Day Two

Thursday June 29, 2017

14.05 | Panel Discussion: Is There a Regulatory Framework That Is Relevant for the Microbiome?

Sarkis Mazmanian
Co-founder
Axial Biotherapeutics

Sarkis K Mazmanian, PhD, is the Louis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology (Caltech). He is a Phi Beta Kappa graduate from the University of California, Los Angeles, where Dr. Mazmanian also received his PhD training in microbiology and immunology. He was a Helen Hay Whitney Post-doctoral Fellow and subsequently appointed assistant professor at Harvard Medical School in 2006, and later that year moved to Caltech. Dr. Mazmanian has won numerous awards including a Searle Scholar, Young Investigator of the Year at Harvard Medical School, Damon Runyon Innovation Award, was named by Discover Magazine as one of the “Best Brains in Science under 40”, “Life Science Superstar” by Genetic Engineering and Biotechnology News, and recently received the MacArthur Foundation “Genius” award. His laboratory focuses on the study of beneficial bacterial molecules from the human gut microbiome as novel therapies for immunologic and neurologic disorders, with a specific focus on developing probiotic treatments for autism. He is a founder of 2 biotech companies, and has or currently serves on the Scientific Advisory Board of over a dozen companies, academic centers and not-for-profit foundations.

Workshop C

Tuesday 27th June

15.00 |

Mind your gut: Harnessing the link between the human gut microbiome and the Central Nervous System to develop new therapeutics for neurological diseases

David Donabedian
CEO and Co-Founder
Axial Biotherapeutics

David H. Donabedian, Ph.D., will serve as Chief Executive Officer of Axial and will also serve on its Board.  Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group. He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.

Workshop C

Tuesday 27th June

15.00 |

Mind your gut: Harnessing the link between the human gut microbiome and the Central Nervous System to develop new therapeutics for neurological diseases

Day Two

Thursday June 29, 2017

15.15 | Identifying Traits to Successful Financing for Next Generation Microbiome Companies

Nur Hasan
Vice President and Head of R&D
CosmosID

Dr. Nur A Hasan is a molecular biologist with over 15 years of experience in microbial genomics, metagenomics, molecular ecology, infectious disease diagnosis and public health. Dr. Hasan is Vice President and Head of R&D at CosmosID. In addition to leading the Science Team at CosmosID, Hasan is an adjunct associate professor at the University of Maryland Institute of Advanced Computer Studies and the Center for Bioinformatics and Computational Biology in College Park, MD. Dr. Hasan received his Bachelor and Masters in Microbiology and M.B.A in Marketing and Ph.D. in Molecular Biology.

Workshop B

Tuesday 27th June

11.30 |

How to Harness and Utilize Bioinformatics for the Microbiome

Manoj Dadlani
CEO
CosmosID

Manoj Dadlani, M. Eng., is the Chief Executive Officer at CosmosID.  He is a Cornell University graduate in biological engineering and served as head of the US branch of Applied Value Management Consulting. He subsequently transitioned to the investment side of the Applied Value Group, which is the lead investor in CosmosID.

Workshop B

Tuesday 27th June

11.30 |

How to Harness and Utilize Bioinformatics for the Microbiome

Vince Wacher
Product Development Consultant
Synthetic Biologics

Vince Wacher, PhD is an entrepreneurial biotechnology/pharmaceutical industry professional with over 22 years of experience successfully leading corporate strategy, partnering, research, product development, and intellectual property programs for start-ups, small companies and new business units within large companies. Prior to Synthetic Biologics Inc., Vince was CEO of Verva Pharmaceuticals Ltd., where he advanced a repurposed medicine to successful phase 2 clinical proof-of-concept testing in type 2 diabetes and discovered a new mitochondrial mode-of-action with expansion applications in NAFLD/NASH, weight loss and mitochondrial diseases. Vince has designed, implemented, and/or analyzed discovery, preclinical and clinical programs in diverse therapeutic areas, including metabolic, cardiovascular, gastrointestinal, oncology, infection, immunosuppression, drug delivery and drug repurposing. He received an Eastman Business Builder Award in 2004 for his work with Eastman Chemical Company (Fortune 500) in advancing their drug delivery technologies. He received his PhD from the University of California, Berkeley and was a post-doctoral scholar in pharmacokinetics and metabolism with Dr Leslie Z Benet at the University of California, San Francisco.

Day One

Wednesday June 28, 2017

17.30 | Targeting Specific Microbiota to Influence Therapeutic Outcomes for Irritable Bowel Syndrome with Constipation (IBS-C)

Trevor Lawley
CSO
Microbiotica

Day One

Wednesday June 28, 2017

09.00 | Culturing The "Unculturable" to Harness the Therapeutic Potential of the Human Intestinal Microbiome

Michelle Trucksis
Chief Medical Officer
Seres Therapeutics

Michele (Shelley) Trucksis is the Executive Vice President and Chief Medical Officer of Seres Therapeutics, Inc. ("Seres"). Dr. Trucksis has 25 years of experience in medicine and infectious diseases. Prior to joining Seres, she served as Executive Director of Merck Research Laboratories with responsibility for clinical and global product development functions and development strategy in antibacterials, antifungals, and anti-cytomegalovirus drug candidates. Dr. Trucksis earned her B.S. in medical technology from Youngstown State University, her Ph.D. in biochemistry from Kent State University, and her M.D. from Case Western Reserve School of Medicine. She completed her internship and residency in Internal Medicine at Yale-New Haven Hospital and her infectious diseases fellowship training at the Massachusetts General Hospital of Harvard Medical School.

Day One

Wednesday June 28, 2017

16.20 | Clinical Trials with Microbiome Therapeutics: Rethinking Medical Therapy

Rodolphe Clerval
Chief Business Officer
Enterome

Day One

Wednesday June 28, 2017

14.55 | Drugs from bugs – How metagenomic dataset delivers druggable targets

Isil Tuzun Weber
Process Engineer
SynCo Bio Partners

Day One

Wednesday June 28, 2017

17.05 | Human Microbiota: Proof of Concept to Production

Kathryn Iverson
Senior Analyst
Second Genome Solutions

Before coming to Second Genome Kathryn helped develop software tools and techniques to analyze the human gut microbiome and its role in health and disease at the University of Michigan. Her previous work was focused on developing new approaches to study the microbiome with applications in colorectal cancer, clostridium difficile infection and healthy populations. This included work as a developer for the microbial ecology software package mothur. Kathryn takes an interdisciplinary approach to microbial informatics using methods from ecology, evolutionary biology, statistics and computer science to provide insights into microbial communities and their interactions with each other and the environment. Kathryn has a masters degree in Bioinformatics from University of Michigan.

Alessio Fasano, MD
Professor of Pediatrics
Harvard Medical School

Alessio Fasano, MD, is Professor of Pediatrics at Harvard Medical School and Director of the Mucosal Immunology and Biology Research Center (MIBRC) at MassGeneral Hospital for Children. Dr. Fasano’s current research expertise encompasses basic science focused on bacterial pathogenesis, gut microbiome composition and function in health and disease, the regulation of gut permeability, and intestinal mucosal biology and immunology, as well as translational science focused on the role of impaired intestinal barrier function in the pathogenesis of autoimmune and inflammatory diseases, including celiac disease and type 1 diabetes. He was responsible for the discovery of zonulin, a protein involved in the regulation of tight junctions, which is released in conditions of dysbiosis.  Current research directed by Dr. Fasano is focused on the basic science of the gut microbiome and intestinal mucosal biology, as well as translational science focused on interventional clinical trials in autoimmune and inflammatory diseases. He is founding co-chair of the MGH Research Institute’s Microbiome Think Tank, which regularly brings together researchers, clinicians, entrepreneurs and other interested parties to discuss opportunities in the emerging field of microbiome research and therapeutic applications for microbial dysbiosis.

Workshop C

Tuesday 27th June

15.00 |

Mind your gut: Harnessing the link between the human gut microbiome and the Central Nervous System to develop new therapeutics for neurological diseases

Paul Carlson
Principal Investigator
FDA

Paul Carlson, Ph. D., is a principal investigator in the Laboratory of Mucosal Pathogens and Cellular Immunology, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA.  He received his PhD from the University of Pittsburgh and performed postdoctoral research at the University of Michigan in the laboratory of Phil Hanna.  Since starting his laboratory at FDA in 2015, Dr. Carlson’s research has focused on infections caused by the enteric pathogens Clostridium difficile and Vancomycin resistant Enterococcus species.  The laboratory has projects researching mechanisms of C. difficile pathogenesis, development of genetic tools to study C. difficile, host response to C. difficile, the role of the microbiome in C. difficile infections, microbiome development, and bacteriophage therapy against VRE.  His regulatory responsibilities include product review for fecal microbiota transplantation (FMT) and defined live biotherapeutic products as well as bacteriophage biologics.

Day Two

Thursday June 29, 2017

12.35 | Regulation of Microbiota-Based Products

14.05 | Panel Discussion: Is There a Regulatory Framework That Is Relevant for the Microbiome?

Nikole Kimes
Co-Founder and VP
Siolta Therapeutics

As a former NSF Graduate Research Fellow (2007-2010), Nikole completed my Ph.D. in the lab of Pamela J. Morris at the Medical University of South Carolina in the Marine Biomedicine and Environmental Sciences program. In Spain, Nikole continued microbial ecology and genomics research as a postdoctoral fellow at the Universidad Miguel Hernández with Francisco Rodriguez-Valera (2012-2014) through the European Union FP7 MaCuMBA project. Utilizing genomic and metagenomic sequencing, coupled with more traditional phenotypic and physiological techniques, Nikole investigated the ecological impact of individual community members, interactions between different community members, and community function as a whole. More recently, Nikole joined Susan V. Lynch’s lab (2014-2016) in order to apply my experience in microbial ecology and function to the human system. There she investigated the role of the human microbiome in developing and maintaining immune tolerance and preventing inflammatory diseases (e.g., asthma and colitis) in humans. Currently, Nikole has transitioned from UCSF to our (Susan Lynch, Samir Kaul, and Nikole Kimes) newly formed biotech company that is focused on rationally designing microbial consortia that will provide prevention and/or treatment against inflammatory diseases.

Day Two

Thursday June 29, 2017

14.05 | Panel Discussion: Is There a Regulatory Framework That Is Relevant for the Microbiome?

Rita Colwell
Distinguished Professor
University of Maryland and John Hopkins University

Dr. Rita R. Colwell is Distinguished University Professor at the University of Maryland, College Park and Johns Hopkins University Bloomberg School of Public Health and Chairman and Chief Science Officer, CosmosID, Inc.  Her interests are focused on genomics, biodiversity, and molecular microbial systematics and ecology. Dr. Colwell is an honorary member of the microbiological societies of the UK, Australia, France, Israel, Bangladesh, India and the U.S. Dr. Colwell served as the 11th Director of the National Science Foundation from 1998 to 2004.  She has authored/co-authored 19 books and over 800 scientific publications.  She is a member of the National Academy of Science and has been awarded the Stockholm Water Prize, Order of the Rising Sun, Japan, and the US National Medal of Science.

Day Two

Thursday June 29, 2017

10.05 | Role of the Microbiome in Diagnostics and Pharma Discovery

Damian Rafal Plichta
Director of Bioinformatics
Clinical Microbiomics

Damian Rafal Plichta, PhD, is the Director of Bioinformatics at the Clinical-Microbiomics. During his doctoral and post-doctoral work at the Technical University of Denmark he became an expert in shotgun metagenomics data analysis. He has been involved in reference-free identification of gut microbes, profiling of microbial growth from sequencing data and studying microbiome dynamics of fecal bacteriotherapy in IBD. Damian has been a visiting PhD student in Joel Hirschhorn’s laboratory at Boston Children’s Hospital and Broad Institute of MIT and Harvard, where he studied human genetics and pathway-level eQTLs.

Day One

Wednesday June 28, 2017

11.30 | Microbial Adaptations of the Microbiome

Julia Cope
Director of Scientific Operations
Diversigen

Dr. Julia Cope is a microbiologist and plant pathologist with training in bioinformatics, and statistics. Her postdoctoral training included work in human microbiome projects for both research and clinical trials at the Texas Children’s Microbiome Center of Texas Children’s Hospital. She currently works with Diversigen, Inc. as the Director of Scientific Operations spearheading pre-clinical and clinical projects in the Microbiome on Human and Animal Health. She has extensive experience in microbiome study design, handling of various sample types, multiple sequencing platforms and the underlying bioinformatics analysis.

Day One

Wednesday June 28, 2017

10.00 | Microbiome Tools and Trends for the Pharmaceutical Industry

Kirk Beebe
Director of Application Science
Metabolon

Kirk Beebe has been an active scientist for over two decades with an interest in translating technological and method innovations to address fundamental biological questions. He received his Ph.D. in biochemistry from Ohio State University where he advanced the understanding of substrate selection of mammalian signaling proteins by developing an innovative chemical biology approach. Following this, he was a post-doctoral scientist and senior research associate at the Scripps Research Institute where he and Professor Paul Schimmel uncovered mechanistic links between genetic code fidelity and disease. After initiating his industry career at Talecris Biotherapeutics (formerly Bayer HealthCare, Biological Products), Kirk joined Metabolon in 2007 and has emerged as a recognized leader for the application of metabolomics in translational research, oncology and frontiers such as the microbiome.

Day One

Wednesday June 28, 2017

14.25 | The Essential Ingredients for Decoding the Microbiome with Metabolomics

Mike Frodsham
Pharmaceutical Development Manager
Quay Pharma

For the past 12 years, Mike has been responsible for the development activities of over 150 non-sterile projects. Typically working with NCE’s to develop drug products for first in human studies Mike is well versed not only in the technical challenges facing drug product development, but also the commercial requirements necessary to achieve project milestones and meet clinical demands.  Most recently the team at Quay Pharma have been working on the oral delivery of live bio-therapeutics for a number of clients.
Mike has an MSc in Industrial Pharmaceutical Sciences (Manchester University), was previously Development Projects Manager and Galpharm International and Principal Formulation Scientist at SSL international.

Day One

Wednesday June 28, 2017

15.10 | Oral Delivery of Live Bio-Therapeutics: Drug Product Development for FIM Studies

Cosmas Giallourakis
Scientific Director- Gastroenterology Drug Discovery Unit
Takeda

Day Two

Thursday June 29, 2017

10.35 | Extended Q&A Discussion- The Big Pharma Perspective Towards the Microbiome

Els van Hoffen
Project Manager, Health
NIZO

Els van Hoffen is currently senior scientist Nutrition and Health at NIZO. She was trained as immunologist, and after her PhD, she worked for many years in academia as research group leader with a focus on dermatology and food allergy. At NIZO, she is involved in the design and execution of innovative human clinical studies for customers in the area of Nutrition and Personal care, with a focus on host-microbe interaction in relation to health and disease.

Day Two

Thursday June 29, 2017

11.35 | Validation of the Intellicap® System as a Tool to Study Changes in the Small Intestinal Microbiota in a Dietary Intervention Study

Gregory Lambert
CEO
TargEDys

Gregory LAMBERT carrier is split between biotech and pharma where he occupied the jobs of VP R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities covered innovation,  CMC, pre-clinical and Clinical development in Europe and north America. He was also in charge of the IP, involved in the Business development and general manager.  Gregory is inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development several pharmaceutical products from the laboratory to market authorizations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Day One

Wednesday June 28, 2017

09.30 | Control of the Appetite Through the Microbiome

Ross Youngs
CEO
Biosortia Pharmaceuticals

Mr. Youngs has over 30 years of inventing products, technologies and processes for a variety of industries. Mr. Youngs holds over 75 patents worldwide and is driven to innovate by a focus on better, faster and less expensive. Recent major innovations have included an R&D 100 Award for collaboration on biopolymer technologies. In 2009, the Company was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology which helped lead to the development of Biosortia’s drug discovery platform. In 1998, Mr. Youngs was awarded the Ernst & Young Ohio Entrepreneur of the Year award and the U.S. Small Business Administration honored Mr. Youngs as their national “Business Person of the Year” in a presentation made by Vice President Al Gore.  

Day Two

Thursday June 29, 2017

16.30 | Panel Discussion: Optimizing Investment for Next Generation Microbiome Companies

Gerard Honig
CEO
Symbiotic Health

Gerard founded Symbiotic Health in 2013 to develop microbiome-based therapeutics to address critical public health challenges. He directs all aspects of the company’s strategy and operations. He has received numerous awards for this work, including the FIGHT CDIFF Innovator’s Award from the Peggy Lillis Memorial Foundation. In addition to his role at Symbiotic Health, Gerard recently joined the Crohn’s & Colitis Foundation as Translational Research Manager to advance product development opportunities in IBD through a new venture philanthropy program. Gerard, a New York native, received his bachelor’s degree from Columbia University and received a PhD in Biological Sciences from the University of California, San Francisco, where he held a Howard Hughes Medical Institute fellowship. He later worked in microbiome research and pathogenesis with Dan Littman and Betty Diamond.

Day One

Wednesday June 28, 2017

13.40 | Targeted Delivery of Cells and Proteins to the Lower Gastrointestinal Tract for Local Therapeutic Action: Opportunities for the Development of Microbiome-Sparing Antimicrobials

Patrice Garnier
CEO
AMAbiotics

Patrice Garnier is Chief Executive Officer for Amabiotics (www.amabiotics.com), a biopharmaceutical company developing innovative microbiome medicines to fight age-related diseases; the lead candidate is AMA-101, a potential first-in-class therapy for Parkinson’s Disease. Dr. Garnier is an entrepreneur with 20 years of experience leading High-tech companies. Prior to joining Amabiotics in 2013, he founded and served for 9 years as CEO of Genostar (www.genostar.com), a bioinformatics company that delivers genome to metabolome solutions for data analysis and management. He also co-founded IgenBio (www.igenbio.com) in 1993, an US based company which develops genome analysis products and services for the life science industry. In 1996 he has launched Novius (www.novius.com), an innovative web agency that he leads until selling the company in 2000 to Ariane ii, a publically traded Belgian IT company.
Dr. Garnier holds an MSc in quantum physics from the École Normale Supérieure in Paris. He completed his PhD in nanotechnology in Professor Catherine Brechignac’s group at the Laboratoire Aimée Cotton, CNRS.

Day Two

Thursday June 29, 2017

16.00 | From Microbiome Exploration to Effective Innovative Therapy: Key Points for a Financial Strategy

Ken Blount
Head of External Research
Rebiotix

Dr. Blount most recently was an Associate Research Scientist/Scholar, Translational Research Coordinator at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, where he established five new clinical-scientist translational research collaborations in oncology.  In addition, Dr. Blount was the co-founder and Director of Biology at BioRelix, a start-up biotechnology company with a platform of novel C. difficile antibiotics. Dr. Blount received his Ph.D. in Chemistry and Biochemistry at the University of Colorado, Boulder and conducted his post-doctoral fellowship at the National Institute of Health at the University of California, San Diego, Department of Chemistry.  

Day Two

Thursday June 29, 2017

14.45 | Business, Regulatory and Clinical Challenges in Bringing Microbiota based Drugs to Market

Colleen Cutcliffe
CEO & Co-founder
Whole Biome

Colleen Cutcliffe is a Biochemist and Molecular Biologist with over a decade of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors.  Colleen is currently the CEO and Co-Founder of Whole Biome, Inc., a San Francisco-based start up that is ushering a revolution in patient care by providing physicians with diagnostics and therapeutics that target the microbiome. Prior to Whole Biome, Colleen served as the Senior Manager of Biology at Pacific Biosciences and before that, as a Scientist in the Parkinson’s Disease discovery group at Elan Pharmaceuticals. Colleen completed her postdoctoral research at Children’s Memorial Hospital in Chicago, her Ph.D. in Biochemistry and Molecular Biology at Johns Hopkins University and her B.A. in Biochemistry at Wellesley College

Day One

Wednesday June 28, 2017

12.00 | How to Better Utilize Analytics for Advanced Microbiome Classification & Pathway Prediction

Day Two

Thursday June 29, 2017

16.30 | Panel Discussion: Optimizing Investment for Next Generation Microbiome Companies

Michael Step
CEO
Ritter Pharmaceuticals

Prior to joining Ritter, Mr. Step was the Senior Vice President of Corporate Development for Santarus, Inc., now a wholly owned subsidiary of Salix Pharmaceuticals, Inc. Mr. Step served in this role for nine years up until the 2014 sale of Santarus to Salix. Mr. Step was responsible for leading all licensing and M&A activities at Santarus and was a member of its executive team. Prior to his tenure at Santarus, Mr. Step held various commercial and business development roles at Amylin Pharmaceuticals for 5 years, culminating in the role of Vice President of Corporate Development and was responsible for leading Amylin’s license of Byetta to Eli Lilly. Before joining Amylin, Mr. Step was Sr. Director of Business Development at Dura Pharmaceuticals and served in licensing, management and sales roles at Hoffmann-La Roche and Syntex Labs. Mr. Step has an MBA degree in marketing and finance from the USC Marshall School of Business and an undergraduate degree from Vanderbilt University.

Day One

Wednesday June 28, 2017

16.50 | Developing a Successful Clinical Trial & Manufacturing Program for Effective Treatment against Lactose Intolerance

Guy Harmelin
CEO & Co-Founder
RondinX

Day One

Wednesday June 28, 2017

12.30 | Growth Dynamics Based Target Discovery

Mark Bodmer
CSO
Evelo Biosciences

Mark Bodmer joined Evelo as Chief Scientific Officer and president of R&D from UCB where he was head of New Medicines Therapeutics leading UCB's research in immunology, neurology and bone disease.  Prior to joining UCB, he served as senior vice president of immunoinflammation, at GlaxoSmithKline, where he was also previously head of metabolic and cardiovascular disease drug discovery. Mark previously served as chief executive officer at three biotech companies: Hexagen, Lorantis and Biotica. He received his Ph.D. from Cambridge University.

Day Two

Thursday June 29, 2017

14.05 | Panel Discussion: Is There a Regulatory Framework That Is Relevant for the Microbiome?

Miguel Barbosa
CSO
Assembly Biosciences

Miguel Barbosa, PhD, Chief Scientific Officer of the Microbiome Program, has more than two decades of experience leading drug discovery and development programs at major pharmaceutical and biotechnology companies. Until 2015, Dr. Barbosa was Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, where he oversaw immunology R&D and new program initiatives, including establishing the foundation for, and then leading, Johnson & Johnson's new microbiome enterprise. Earlier in his career, Dr. Barbosa held positions of increasing responsibility managing new drug R&D programs at prominent biopharmaceutical firms, including Centocor, Signal Pharmaceuticals, TRL USA, Chugai Biopharma and Mirna Therapeutics. Dr. Barbosa received a BS degree from the University of California, Davis and a PhD from the University of California, Los Angeles. He completed a post-doctoral fellowship at the National Cancer Institute.

Day One

Wednesday June 28, 2017

17.15 | Realizing the Promise of the Microbiome: Using Rigorous Pharmaceutical Principles of Drug Development

Karim Dabbagh
CSO
Second Genome

Day One

Wednesday June 28, 2017

08.30 | Mining the Microbiome for New Therapeutic Candidates for Chronic Diseases

Zain Kassam
Chief Medical Officer
OpenBiome

Dr. Zain Kassam is the Chief Medical Officer at OpenBiome. He is a gastroenterologist, internal medicine physician and epidemiologist. Zain was named a Top 40 Under 40 Healthcare Innovator by MedTech and is a Scientific Advisory Board member for the American Gastroenterological Association Center for Gut Microbiome Research & Education. Dr. Kassam's research focuses on innovative microbiome-directed therapies that deeply impact human health and disease. He has authored over 100 peer-reviewed abstracts, publications and book chapters and holds grants from the CDC, CCFA and private foundations. Dr. Kassam received his MPH degree with a focus on Clinical Trials at Harvard University on a Frank Knox Fellowship and completed his post-doctoral training in microbiome engineering at MIT. He completed both his Internal Medicine and Gastroenterology training at McMaster University, where he was the Chief Medical and Chief Gastroenterology Resident and was awarded the National Resident Leadership Award by the Royal College of Physicians and Surgeons of Canada.  

Day One

Wednesday June 28, 2017

15.50 | The Next Generation Microbiome Clinical Trial

John Hambor
Director Research Beyond Borders
Boehringer Ingelheim

Day Two

Thursday June 29, 2017

10.35 | Extended Q&A Discussion- The Big Pharma Perspective Towards the Microbiome

09.10 | Establishing the Causal Role of Bacteria in Human Health and Disease

Dirk Gevers
Global Head of the Janssen Human Microbiome Institute
Janssen R&D

Dirk Gevers, Ph.D., is Global Head of the newly created Janssen Human Microbiome Institute (JHMI). The creation of the JHMI will deepen the Janssen R&D’s leadership, scientific understanding and capabilities in this emerging and exploding area of science. Dirk joined from his most recent role as Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard. In this position, Dirk served as a scientific liaison between different organizational components, including the Broad Institute’s data generation platforms and both clinical and analytical collaborators on a number of microbiome-related projects. Dirk’s research efforts at the Broad Institute included the characterization of the microbial imbalance associated with diseases such as Crohn’s disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health (NIH) Human Microbiome Project (HMP), holding a leading role in the Data Analysis Working Group, consisting of over 50 investigators focused on human microbiome research. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and Massachusetts Institute of Technology (MIT) in bioinformatics, comparative and evolutionary genome analysis and microbial ecology.    

Day Two

Thursday June 29, 2017

10.35 | Extended Q&A Discussion- The Big Pharma Perspective Towards the Microbiome

10.20 | Innovating Science, Technology and Business Models to Deliver on the Promise of the Microbiome

Arpita Maiti
Director of External R&D Innovation
Pfizer

As Director, External R&D Innovation (ERDI), Arpita is a member of the external opportunities (discovery to POC) search and evaluation team for Inflammation & Immunology at Pfizer.  ERDI is an externally-focused scientific team of PhDs / MDs, embedded within Pfizer research groups, that identifies late-breaking science that forming the basis of innovative therapies, and drives related collaborations that deliver value to Pfizer, its partners, and patients.  Prior to Pfizer, she was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals.  Arpita got her start in biotech at Angiotech Pharmaceuticals, heading the Cell Biology & Drug Screening group.  She trained as an immunologist and has a PhD and MSc in Immunology from UBC and a BSc from Trinity College, UofT.  In addition to participating/presenting at pharma innovation and microbiome conferences, she co-organized the 12th World Congress on Inflammation held in 2015, and serves on the board of the Inflammation Research Association as its Past-President.  

Day Two

Thursday June 29, 2017

10.35 | Extended Q&A Discussion- The Big Pharma Perspective Towards the Microbiome

09.50 | Promise and Pitfalls of Microbiome-Modulating Methods for Inflammatory and Autoimmune Diseases

Dario Gutierrez
Immuno-Biology Lead
Merck

Dr.  Dario Gutierrez is the Immuno-biology Lead for the Merck Research Labs Cambridge Exploratory Science Center.  Previously, he led the Immune Tolerance group at Evelo Biosciences in Cambridge MA. He received a bachelor of science in Chemistry from California State University, San Bernardino, a PhD from the Department of Molecular Physiology and Biophysics in the laboratory of Dr. Alyssa Hasty at Vanderbilt University, and performed a postdoctoral fellowship in the laboratory of Hans-Reimer Rodewald at the German Cancer Research Center (DKFZ) in Heidelberg, Germany.  He has authored several publications on the role of the immune system in metabolic and autoimmune diseases, and current work focuses on understanding the modulation of human immune responses by commensal and pathogenic microorganisms.

Day Two

Thursday June 29, 2017

10.35 | Extended Q&A Discussion- The Big Pharma Perspective Towards the Microbiome

09.25 | Exploring the Contribution of the Microbiome to Immune Responses

Paul Miller
Chief Scientific Officer
Synlogic

Dr. Paul Miller joined Synlogic in 2014 as chief scientific officer and is accountable for all aspects of discovery research and platform expansion at the company. Previously, Paul was the vice president of infection biology at AstraZeneca, where he was responsible for the early discovery portfolio and strategy while also leading several external collaborations. Prior to Astra-Zeneca, Paul was the chief scientific officer for antibacterial research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox, and also successfully advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase II studies. A microbial geneticist by training, Paul began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated modern molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Paul received his Ph.D. in microbiology and immunology from the Albany Medical College, and conducted post-doctoral studies at the National Institutes of Health. He has also served as a member of the Institute of Medicine’s Forum on Microbial Threats.

Workshop A

Tuesday 27th June

08.00 |

Artificial Microbiome Products- The Role of Synthetic Biology in the Microbiome

Xavier Maniere
Head of R&D Operations
AMAbiotics

Xavier Manière is a pharmacist, PhD. He did his PhD studying the link between bacteria an aging in C. elegans. He then join the Laboratoires Servier to develop physiologically relevant high Throughput preclinical models to validate hits from HTS. He is now at the the head of R&D operations at AMAbiotics where he develop disease modifying candidates from microbial metabolites against age-related diseases.

Day One

Wednesday June 28, 2017

12.15 | Rethink the Preclinical Paradigm to Identify Promising Therapeutic Candidates

Sonia Timberlake
Director of Data Science
Finch Therapeutics

Day One

Wednesday June 28, 2017

13.55 | Designing Microbial Therapeutics with a Human-First Discovery Platform

Douglas Crawford
Managing Director
Mission Bay Capital

Douglas Crawford’s goal is to help entrepreneurial scientists create successful startups. To this end, Doug and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Crawford created and manages QB3@953.  This state-of-the-art co-working laboratory program in San Francisco allows entrepreneurs to rapidly generate data without getting bogged down in facility management.  Rather than spending months getting a facility up and running, QB3@953 startups can generate important data in their first week. In the first 3 years, this program has helped launch 74 companies that have raised over $760M.  This incubator program reflects Doug’s passion for startups and his eagerness to help entrepreneurs overcome challenges. Doug is also the Managing Director of Mission Bay Capital and has overseen the investment in 25 companies, 4 of which have already enjoyed successful exits (Calithera, iPierian, Redwood Biosciences and Zephyrus).  He is a board member of Avexegen, Circle Pharma, Delpor, Magnamosis, Magnap, Tangible Sciences, and Viewpoint. Crawford received his PhD in biochemistry from UCSF.  Loves traveling with his family, making great pizza, and killer cappuccinos.

Day Two

Thursday June 29, 2017

16.30 | Panel Discussion: Optimizing Investment for Next Generation Microbiome Companies

Adam D’Augelli
Partner
True Ventures

Adam D'Augelli is a Partner at True Ventures. Growing up, Adam was drawn to startups and technology – early on as a founder of a donation–based record label and a social business in India, then later as a consultant to early-stage technology companies on the East Coast. Building upon this experience, Adam led the creation of "Digital Frontiers," a course at the University of Florida exploring how the Internet and technology are changing the global business landscape. Adam graduated magna cum laude from the University of Florida with a BS and MS in Finance, and was selected as one of the two Four Year Outstanding Scholars in his graduating class. Outside the office, Adam can be found at live music events both inside and outside of San Francisco, participating in half marathons, or reading GigaOM Pro Reports in Golden Gate Park.

Day Two

Thursday June 29, 2017

16.30 | Panel Discussion: Optimizing Investment for Next Generation Microbiome Companies

Scott Jackson
Group Leader - Complex Microbial Systems
NIST

Scott Jackson joined NIST in 2014 and currently serves as the leader of the recently created Complex Microbial Systems group. When he isn’t immersed in his studies of gut bacteria, Scott is usually geeking out on various techie hobbies and riding his mountain bike off-road and around Baltimore City’s Inner Harbor.

Day Two

Thursday June 29, 2017

14.05 | Panel Discussion: Is There a Regulatory Framework That Is Relevant for the Microbiome?

12.05 | Improving Microbiome Measurement Standards to Overcome Regulatory Hurdles